LENZ Therapeutics, Inc.
HealthcareNASDAQ:LENZ · NASDAQ Global Select
+$0.27 today
Vol 0.28M · Avg 0.92M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-28.9%
avg 181.0%
ROIC
-32.0%
avg -30.8%
ROA
-26.8%
avg -382.6%
Analysis
ROA is currently the strongest return metric at -26.8% versus its period average of -382.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Evert Schimmelpennink | President, Chief Executive Officer, Secretary & Director | $1.24M | — | 54 | $77,289.00 | 0.25% |
Marc G. Odrich | Chief Medical Officer | $774,000.00 | — | 67 | $84,200.00 | 0.27% |
Shawn Olsson | Chief Commercial Officer | $724,600.00 | — | 43 | $84,200.00 | 0.27% |
Daniel R. Chevallard | Chief Financial Officer | $680,368.00 | — | 46 | $12,886.00 | 0.04% |
James W. McCollum | Co-Founder & Director | $40,000.00 | — | 71 | $10,500.00 | 0.03% |
Kris Gambelin | Senior Vice President of Regulatory & Clincal Operations | — | — | — | — | — |
David Choromanski | Vice President of Marketing | — | — | — | — | — |
Domenick Porfidia | Vice President of Sales | — | — | — | — | — |
Melissa Rosness | Senior Vice President of Manufacturing Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
6
$654,870.93
Sells
35
$56.71M
Net Sentiment
$56.06M
Net selling
Most Active
Versant Venture Capital VI, L.P.
33 transactions
1–10 of 41
Analysis
Insiders reported 6 buys worth $654,870.93 and 35 sells worth $56.71M over the last 12 months. That adds up to net selling of $56.06M. Versant Venture Capital VI, L.P. was the most active insider with 33 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Nanobiotix S.A.
NASDAQ:NBTX
$1.80B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
GH Research PLC
NASDAQ:GHRS
$1.45B
Savara Inc.
NASDAQ:SVRA
$1.08B
ARS Pharmaceuticals, Inc.
NASDAQ:SPRY
$969.20M
Arbutus Biopharma Corporation
NASDAQ:ABUS
$841.51M
Geron Corporation
NASDAQ:GERN
$737.75M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
Rezolute, Inc.
NASDAQ:RZLT
$385.17M
Who manages LENZ?
LENZ Therapeutics, Inc. (LENZ) lists 9 active executives. The top listed executive is Shawn Olsson, Chief Commercial Officer.
Are LENZ insiders buying or selling?
Recent insider activity shows net selling of $4.20M.
Explore More
Continue the stock analysis
Jump to another research area for this company.